QIAGEN N.V. $QGEN Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its stake in QIAGEN N.V. (NYSE:QGEN - Free Report) by 5.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 113,046 shares of the company's stock after purchasing an additional 5,593 shares during the period. Public Sector Pension Investment Board owned about 0.05% of QIAGEN worth $4,478,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Nuveen LLC bought a new position in shares of QIAGEN in the first quarter worth about $44,078,000. Invesco Ltd. grew its holdings in shares of QIAGEN by 13.5% in the first quarter. Invesco Ltd. now owns 449,638 shares of the company's stock worth $18,053,000 after purchasing an additional 53,383 shares during the last quarter. Forsta AP Fonden grew its holdings in shares of QIAGEN by 185.8% in the first quarter. Forsta AP Fonden now owns 29,368 shares of the company's stock worth $1,179,000 after purchasing an additional 19,093 shares during the last quarter. Citigroup Inc. grew its holdings in shares of QIAGEN by 51.4% in the first quarter. Citigroup Inc. now owns 473,388 shares of the company's stock worth $18,754,000 after purchasing an additional 160,799 shares during the last quarter. Finally, Caisse Des Depots ET Consignations grew its holdings in shares of QIAGEN by 7.3% in the first quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company's stock worth $53,374,000 after purchasing an additional 91,357 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

QIAGEN Stock Down 0.0%

Shares of QGEN stock traded down $0.0140 during mid-day trading on Thursday, hitting $49.1860. 430,098 shares of the stock traded hands, compared to its average volume of 1,371,794. The stock has a market cap of $10.93 billion, a P/E ratio of 29.06, a P/E/G ratio of 2.58 and a beta of 0.64. The stock's fifty day moving average is $48.53 and its two-hundred day moving average is $43.81. QIAGEN N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. QIAGEN's revenue was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities analysts predict that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Announces Dividend

The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were given a $0.25 dividend. This represents a dividend yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio (DPR) is presently 14.79%.

Analyst Ratings Changes

A number of research firms have recently commented on QGEN. Barclays began coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. UBS Group upped their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Bank of America upped their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Finally, Cowen reaffirmed a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $49.69.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.